Vaxxinity, Inc. (VAXX) OTC

0.04

-0.003(-6.98%)

Updated at September 05 12:44PM

Currency In USD

Vaxxinity, Inc.

Address

1717 Main Street

Dallas, TX 75201

United States of America

Phone

254 244 5739

Sector

Healthcare

Industry

Biotechnology

Employees

57

First IPO Date

November 11, 2021

Key Executives

NameTitlePayYear Born
Ms. Mei Mei Hu J.D.Co-Founder, President, Chief Executive Officer & Director345,1431983
Mr. Louis Garfield Reese IVCo-Founder & Executive Chairman of the Board275,5751982
Ms. Sumita Ray J.D.Chief Legal, Compliance & Administrative Officer and Corporate Secretary465,5571974
Dr. Jean-Cosme Dodart Ph.D.Chief Scientific Officer0N/A
Mr. Mark Joinnides MSEChief of Staff0N/A
Mr. Jason Pesile CPA, M.B.A.Chief Accounting Officer01973
Dr. Manal Morsy M.B.A., M.D., PH.D.Chief Regulatory Officer0N/A

Description

Vaxxinity, Inc., a biotechnology company, focuses on developing product candidates for human use in the fields of neurology and coronaviruses in the United States. The company engages in developing UB-311 that targets toxic forms of aggregated amyloid-b in the brain to fight Alzheimer's disease (AD) that is in phase 2 clinical trial; UB-312 that targets toxic forms of aggregated a-synuclein in the brain to fight Parkinson's disease and other synucleinopathies, such as Lewy body dementia and multiple system atrophy that is in phase 1 clinical trial; and an anti-tau product candidate for various neurodegenerative conditions, including AD. It is also developing UB-313 that targets calcitonin gene-related peptide to fight migraines; anti-PCSK9 that targets proprotein convertase subtilisin/kexin type 9 serine protease to lower low-density lipoprotein cholesterol and reduce the risk of cardiac events; and UB-612 for neutralizing the SARS-CoV-2 virus, which is in phase 3 clinical trial. Vaxxinity, Inc. was founded in 2014 and is headquartered in Dallas, Texas.